Annual Report 2021 and Notice of AGM

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

Directors' Report and Accounts for the financial year ended 31 January 2021 and Notice of 2021 Annual General Meeting

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, announces that the Directors' Report and Accounts for the year ended 31 January 2021 and the notice of its Annual General Meeting 2021 have now been sent to shareholders and published on the Company's website at www.inspirationhealthcaregroup.plc.uk.

Annual General Meeting and voting

The Annual General Meeting of Inspiration Healthcare Group plc (the "Company") (the "AGM") will be held at 11:30am (UK time) on 25 June 2021 at Unit 2, Satellite Business Village, Fleming Way, Crawley, West Sussex, RH10 9NE.

At the time of approval of the Notice, UK Government social distancing measures and restrictions in response to COVID-19 are due to come to an end on 21 June 2021. In line with this, the Board welcomes the opportunity to invite shareholders to attend the AGM in person. Appropriate COVID-19 safety measures will be in place, and UK Government guidance and legislation will be followed.

What if the situation in relation to COVID-19 changes?

The Board will monitor any changes to the UK Government guidance and legislation in relation to COVID-19.  Should the situation change such that the Board considers that it is no longer possible for shareholders to attend the AGM in person, we will update the AGM information page of our website at www.inspirationhealthcaregroup.plc.uk with the latest information about the impact of Coronavirus on the AGM, including any adjustments to arrangements for the AGM. It is therefore strongly recommended that the website is reviewed before attending the AGM.

Voting by proxy

Shareholders will not receive a hard copy form of proxy for the AGM in the post. Instead, shareholders will be able to appoint a proxy electronically using the link www.signalshares.com. Shareholders will need to log into their Signal Shares account or register if that shareholder has not previously done so. To register shareholders will need their Investor Code, this is detailed on the share certificate or available from our Registrars, Link Group. Proxy votes must be received by no later than 11.30 am on 23 June 2021. Alternatively, shareholders may submit their proxy vote via CREST where applicable.

Request a hard copy form of proxy

Shareholders may request a hard copy form of proxy directly from the Registrars, Link Group on 0371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. Lines are open between 09:00 - 17:30, Monday to Friday excluding public holidays in England and Wales. Alternatively, shareholders can request a hard copy proxy card by emailing [email protected].

Enquiries

About the Group:

www.inspirationhealthcaregroup.plc.uk

Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in critical care & operating theatres with a focus on neonatal care. The Company provides high-quality, innovative products to patients around the world which help to improve patient outcomes, and it actively invests in innovative product opportunities and disruptive technologies.

The Group currently consists of three companies: Inspiration Healthcare Ltd, SLE Ltd and Viomedex Ltd and under these brands the Group sells neonatal intensive care and operating theatre equipment around the world through a network of distributors into over 75 countries. Products range from highly sophisticated capital equipment through to single use disposables all of which can help improve outcomes of extremely sick patients.

In the UK and Ireland the Group offers direct sales for most of its products supported by Technical Service offering on site and return to base repair and maintenance along with 24/7 emergency hire of equipment and long term lease arrangements for its own brand products. The Group also acts as a distributor for 3rd party companies that wish to access the UK and the Republic of Ireland's health systems using the Group's sales and service expertise and knowledge of these healthcare providers. The therapy areas in which we distribute products such as Infusion, Respiratory and Developmental Care add value to our product portfolio.

The Group invests in growth through its Research and Development function holding numerous patents on its technology and has strong links with academic Key Opinion Leaders around the world and supports clinical research in the field of neonatal intensive care.